New Strong Buy Stocks for September 24th

Zacks added Bristol-Myers Squibb, Heritage Insurance, Red Violet, Nomura Holdings and Okeanis Eco Tankers to its Rank #1 (Strong Buy) list after upward current-year earnings-estimate revisions. Consensus EPS estimates rose nearly 9% for Bristol-Myers, 27% for Heritage, 8.8% for Red Violet, 22.5% for Nomura and 60.9% for Okeanis over the past 60 days. The updates are constructive for the named stocks but represent analyst-estimate commentary rather than company-reported financial results.

Analysis

This is a low-information, mechanically generated estimate-revision screen rather than an independent fundamental catalyst; the initial signal is therefore most likely to matter in smaller, less-liquid names where retail and quant flows can briefly amplify visibility. RDVT and ECO have the highest risk of a transient “rank effect” because limited float/liquidity can turn modest incremental demand into outsized moves, but that also makes exits difficult and raises gap risk around earnings.

The revisions have materially different durability. BMY’s upside requires evidence that pipeline/launch execution and legacy-product erosion are improving faster than consensus; absent a guidance change, a single-digit revision is unlikely to overcome the valuation discount attached to patent-expiry risk over 6-18 months. HRTG’s estimates are most exposed to catastrophe losses, reinsurance renewal pricing, and Florida regulatory developments, while ECO’s earnings are fundamentally a tanker-rate trade: spot-rate and fleet-supply data matter far more than sell-side revision momentum.

NMR is the cleaner macro expression if Japanese rates and capital-markets activity continue normalizing, but ADR returns can be overwhelmed by USD/JPY. The contrarian view is that the screen could be late-cycle: sharp revisions often follow already-reported results or rate moves, so chasing the publication-day reaction has poor expected value unless subsequent consensus upgrades and management guidance confirm a second leg over the next 1-3 months.

Key Decisions for Investors

• No broad basket trade: treat the screen as an alert, not a catalyst. Require confirmation from next-quarter consensus revisions, estimate dispersion, and daily liquidity before initiating any position.
• Watch ECO for a tactical 1-3 month long only if VLCC spot rates remain above cash-breakeven and forward charter rates rise; use a 7-10% stop given shipping beta. Falsify on sustained rate deterioration or evidence of accelerated tanker deliveries.
• Prefer a small HRTG long versus short KIE only after verifying hurricane-season loss development and January reinsurance terms; target 10-15% relative upside over 3-6 months, but exit on adverse reserve development, catastrophe losses, or a material combined-ratio guide increase.
• For BMY, avoid chasing revisions. Consider long BMY only if management raises full-year guidance or provides measurable launch traction; otherwise its patent-cliff discount can persist despite near-term EPS upgrades. A BMY long / short XLV pair isolates company execution from defensive-healthcare beta.
• Monitor NMR with USD/JPY: a long NMR position is more attractive if Japanese yield normalization supports net-interest income without a sharp yen appreciation. Falsify if capital-markets revenues weaken, Bank of Japan policy reverses, or USD/JPY falls sharply enough to offset local-equity gains.